Product Description: Cefpodoxime Proxetil-d6 (U-76,252-d6) is deuterium labeled Cefpodoxime Proxetil. Cefpodoxime proxetil is an orally administered broad spectrum third-generation cephalosporin. Cefpodoxime proxetil has anti-bacterial activity. Cefpodoxime proxetil binds to penicillin binding proteins (PBPs) which inhibits peptidoglycan synthesis, finally results in interfering bacterial cell wall biosynthesis[1][2].
Applications: COVID-19-immunoregulation
Formula: C21H21D6N5O9S2
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Iqbal S, et al. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers. Pak J Pharm Sci. 2019 Mar;32(2 (Supplementary)):881-887./[3]Pahwa R, Rana A S, Dhimans S, et al. Cefpodoxime proxetil: an update on analytical, clinical and pharmacological aspects [J]. J Curr Chem Pharm Sc, 2015, 5(2): 56-66.
Molecular Weight: 563.63
Research Area: Infection
Target: Antibiotic;Bacterial;Isotope-Labeled Compounds;Penicillin-binding protein (PBP)
Deutsch
English
